AstraZeneca and Merck’s Lynparza (olaparib) Receives FDA’s Approval for 1L BRCA-Mutated Advanced Ovarian Cancer

 AstraZeneca and Merck’s Lynparza (olaparib) Receives FDA’s Approval for 1L BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and Merck’s Lynparza (olaparib) Receives FDA’s Approval for 1L BRCA-Mutated Advanced Ovarian Cancer

Shots:
  • The approval is based on P-III SOLO-1 trial assessing Lynparza (300 mg bid) as maintenance monothx vs PBO in 391 patients in ratio (2:1) with BRCAm advanced ovarian cancer following first-line Pt-based CT for two years
  • P-III SOLO-1 trial results: reduction in risk of death 70%, patients remained progression free for three years, with safe and well-tolerated
  • Lynparza (olaparib) is PARP inhibitor, targeted for DNA damage response (DDR) pathway deficiencies, including BRCA mutations. In 2017, Merck and AZ collaborated to co-develop and co-commercialize Lynparza globally

Click here to read full press release/ article | Ref: Merck | Image: Axios

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post